{Reference Type}: Journal Article
{Title}: Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®).
{Author}: Naik SP;Zade JK;Sabale RN;Pisal SS;Menon R;Bankar SG;Gairola S;Dhere RM;
{Journal}: Vaccine
{Volume}: 35
{Issue}: 22
{Year}: 05 2017 19
{Factor}: 4.169
{DOI}: 10.1016/j.vaccine.2017.04.025
{Abstract}: Vaccines currently available across the globe are stored and transported in a continuous cold-chain at 2-8°C or below -20°C. A temperature excursion outside this range affects the potency of the vaccines. Such vaccines need to be discarded leading wastage. The Rotavirus disease burden is predominantly reported in developing and low-income countries and therefore, has entered or poised to enter their national immunization programs. These countries already have several limitations for effective storage, maintenance and distribution of vaccines in a cold-chain and this introduction is expected to further stress this fragile ecosystem. To help mitigate the cold chain related issues, SIIPL has developed a thermostable rotavirus vaccine ROTASIIL® which can be stored at a temperature below 25°C for 36months, completely by-passing the standard 2-8°C cold storages. In addition it has the capability to withstand temperatures of 37°C and 40°C for 18months and short term exposure to 55°C. It can also tolerate a temperature shock of being thawed from an extreme cold temperature of -20°C to a high temperature of 42°C. The vaccine contains serotypes G1, G2, G3, G4 and G9 (UK-Bovine reassortant strains procured from National Institute of Health-USA). The vaccine is recently licensed in India.